Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
Researchers developed a free-to-use software tool, PSBench, to verify the accuracy of artificial intelligence-based protein structure predictions. The database includes 1.4 million annotated protein models, verified by experts, and provides reliable information for building more accurate AI systems.
A study published in Nature reveals that a protein called lipocalin 2 (LCN2) is produced by stressed cancer cells to shield them from the immune system. Blocking LCN2 with new drugs enables the immune system to target tumor cells, slowing cancer growth in mice.
Researchers at Case Western Reserve University developed a strategy using ultrasound-activated nanobubbles to break down tumor barriers, making tumors softer and more penetrable to treatment-bearing molecules and immune cells. This breakthrough could fast-track therapy to clinical trials for solid tumors like prostate cancer.
Researchers found patients who retreated with docetaxel had longer overall survival and fewer supportive-care needs compared to those switching to cabazitaxel. The study provides evidence-based options for selected patients previously tolerated docetaxel.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
A new UCLA study found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer. The combination treatment helped patients live long enough to reach surgery, shrank tumors, and produced encouraging survival outcomes.
A new framework proposes a 'three-strata' model to classify gastrointestinal tract cancers, guiding more precise and effective strategies. The review advocates for chemotherapy-free approaches in highly immunogenic tumors and explores optimized combinations with chemotherapy for intermediate-sensitive tumors.
A multi-institutional effort aims to refine relapse prediction by identifying genetic markers in blood samples from patients with rare blood cancer. Analyzing blood samples from 190 patients, researchers found that tiny traces of persistent NPM1 mutation were linked to worse outcomes and lower survival rates.
A study by University of Texas at Dallas bioengineers found that both cancerous and noncancerous colon tissue from young patients with colorectal cancer was mechanically stiffer than in older patients. This stiffness may promote the development of early-onset colorectal cancer, a condition rising over the past 30 years.
Researchers review the molecular mechanisms of mitophagy in breast cancer, highlighting its potential as a biomarker and therapeutic target. The study suggests that strategic modulation of mitophagy can enhance personalized treatment approaches for BC.
The National Comprehensive Cancer Network has published new guidelines for Pediatric Soft Tissue Sarcomas, highlighting the unique characteristics of this childhood cancer. The guidelines focus on rhabdomyosarcoma (RMS), a subtype with varying genetic changes that influence treatment outcomes.
The conference aims to improve genetic studies, clinical best practices and community interventions to combat the increasing cancer incidence rates. It will bring together top cancer-focused minds to promote precision medicine and stimulate multidisciplinary collaborations for cancer solutions.
Research from Salk Institute scientists shows that DNA's dynamic folding process affects gene regulation and expression, with specific regions unfolding at different rates to regulate cell type-specific functions.
Researchers developed AI-IR, a machine learning tool that predicts insulin resistance and implies a link to cancers. The model demonstrated strong predictive power in detecting insulin resistance that BMI alone cannot explain.
A recent clinical trial led by Oregon State University scientists found that the composition of a dog's microbiome is linked to its cancer survival rate. The study identified 11 specific types of bacteria that were associated with longer or shorter survival, suggesting potential biomarkers for predicting treatment response and improvin...
The review outlines how vascular-immune crosstalk affects various diseases, revealing novel therapeutic opportunities. It highlights the shared embryonic origin of blood vessel cells and immune cells, as well as coordinated immune cell trafficking mechanisms.
Researchers have genetically engineered therapeutic CAR T cells that can destroy solid tumors, overcoming a major obstacle in cancer treatment. By silencing prostaglandin E2 signalling, these new cells can recognize and attack cancer cells without suppressing their own immune function.
This review examines cancer-inflammation interplay, translational advances, and clinical strategies. Emerging technologies promise to refine precision therapy, while integrating inflammation-targeting approaches with immunotherapy offers a path to personalized cancer care.
Research by Queen Mary University of London led to changes in NHS guidelines, allowing hundreds of people with advanced bladder cancer to receive fewer chemotherapy cycles. This results in reduced toxic side effects and a better quality of life during treatment.
Charles Swanton has described the evolution of tumors through genetic mutations, explaining why treatments often fail to eliminate them entirely. His discoveries could lead to more accurate diagnostics and improved cancer treatment.
A study from Lund University found that a climate-friendly diet rich in plant-based foods like wholegrains, legumes, fruit, and vegetables leads to better nutritional status compared to traditional diets. Despite lower meat consumption, most participants achieved sufficient amounts of key vitamins and minerals.
Lung cancer in never-smokers (LCINS) is a growing global health challenge with distinct biological and clinical characteristics. The authors emphasize the importance of identifying risk factors, developing better screening tests, and discovering more effective treatment approaches for LCINS.
Researchers developed a PD-L1-binding antigen presenter that redirects antiviral antibodies to target cancer cells, transforming virus-specific immune memory into precision anti-cancer weapons. This strategy has significant potential for treating hard-to-treat cancers and represents a lower-cost, safer avenue for tumor immunotherapy.
The FLOWERS trial demonstrates a significant enhancement in clinical outcomes for NSCLC patients with EGFR and MET mutations when treated with osimertinib plus savolitinib. Patients receiving the combination regimen showed extended progression-free survival and improved tumor response rates compared to those on osimertinib alone.
A case report investigates a woman's development of acute lymphoblastic leukemia and lymphoblastic lymphoma after receiving her second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine, highlighting potential genetic and molecular mechanisms involved in disease pathogenesis.
A new review highlights the growing burden of lung cancer in never-smokers, emphasizing the need for dedicated research, screening, and clinical trials. The study argues that LCINS has distinct causes and biology requiring a different approach to diagnosis and treatment.
The Phase I/II multicenter international CADENZA trial found that 75% of patients with BPDCN treated with pivekimab sunirine achieved a complete response. The treatment delivered the therapeutic drug directly to cancer cells, resulting in rapid cancer cell death with limited targeting of healthy tissue.
Researchers identified a previously unrecognized metabolic defence mechanism in aggressive brain tumours: a sugar-rich shield that protects tumour cells from ferroptosis. The study found that the sugar shield and lipid droplet storage mechanisms cooperate to evade cell death.
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
A new analysis found that rural cancer patients treated locally have similar surgical outcomes to those who traveled to urban facilities. The study used Surveillance, Epidemiology, and End Results data from Medicare-eligible patients with lung or colon cancer, aged 65 or older, residing in rural areas.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
A study by Silent Spring Institute identified dozens of hazardous chemicals in hair extensions, including products made from human hair. The analysis revealed chemicals linked to cancer, hormone disruption, and developmental problems, prompting calls for stronger oversight and policy change.
Researchers at City of Hope have made significant breakthroughs in cancer treatment, immune system regulation and early disease detection. A study found that subtle RNA changes can shape cancer behavior, opening new avenues for precision oncology. In contrast, combining immunotherapy with chemoradiation did not improve survival rates f...
Researchers used DNA barcoding to track cancer cells in solid and liquid biopsies, finding that tumour heterogeneity varies widely depending on necrosis and tumour burden. This study suggests that combining both strategies may provide a more accurate representation of the disease.
Researchers found that an experimental compound SB-216 reduced the growth of pancreatic ductal adenocarcinoma cells by inhibiting oncogenic microtubules and mitochondrial function. This approach may reduce cancer cell adaptation and survival.
A breakthrough study has discovered a genetic defect that weakens the esophageal lining, making it vulnerable to acid damage. The discovery offers new hope for esophageal cancer patients and provides a potential screening tool for family members at high risk of developing the condition.
Dr. David Gius, a renowned physician-scientist and radiation oncologist, has been appointed as the new director of the University of Cincinnati Cancer Center. He brings a robust research portfolio, including active clinical trials and NIH grants, to enhance regional access to superlative care.
A UCalgary study found that adding high doses of vitamin B3 to the treatment plan may help rejuvenate compromised immune cells to kill tumour cells. The clinical trial showed promising results, with 82% of participants free of cancer progression at six-months.
Scientists have identified the FOXO1-KLHL6 axis as a novel therapeutic target to enhance T cell-mediated immune response against tumors. The research found that persistent T cell receptor signaling suppresses the transcription factor FOXO1, leading to the downregulation of the E3 ubiquitin ligase KLHL6 and promoting T cell exhaustion.
A global study found that ropeginterferon alfa-2b controls essential thrombocythemia effectively, improves symptoms and reduces serious complications in patients who can't use hydroxyurea. The therapy is expected to be approved for treatment of high-risk blood cancer.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
A major study has shown that tumour stage at diagnosis is strongly linked to childhood cancer survival across six different cancers. Researchers analysed data from 9,883 children in 27 countries and found significant variation in three-year survival rates between regions, particularly in the UK and Ireland.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A study found that 60.8% of American women prefer in-clinic cervical cancer screening, while 20.4% opt for at-home self-sampling. Marginalized groups, including those with low income and distrust of healthcare systems, are more likely to choose at-home options.
Researchers at the University of Illinois have found that the ABCA1 protein plays a crucial role in directing how myeloid immune cells, particularly macrophages, behave. When ABCA1 is expressed, these cells become better at fighting cancer and supporting T cell function.
Advanced Cancer Research defines a platform for integrating molecular biology, genomics, immunology, engineering, and computational science to understand cancer as a complex disease. The journal prioritizes studies that provide mechanistic depth and bridge disciplinary boundaries.
A new study reveals the CDK12-FOXA1-MDM2-p53 signaling axis promotes prostate cancer development through FOXA1 modification. The study identifies S234 phosphorylation as a critical site, and a CDK12 inhibitor THZ531 effectively blocks this pathway, reducing tumor growth.
Scientists at UNIGE discovered that neutrophils, a type of immune cell, undergo reprogramming to produce chemokine CCL3, promoting cancer growth. This mechanism appears to be a major variable in tumour biology and could serve as an indicator of disease progression.
A new computational tool called PRISM (Precise Identification of Species of the Microbiome) has been developed to settle the controversy over whether microorganisms truly reside in tumors. The tool uses rapid screening and machine-learning models to distinguish genuine microbial signals from artifacts.
A recent cohort study found that individuals diagnosed with cancer in 2020 and 2021 experienced worse short-term survival rates compared to those diagnosed between 2015 and 2019. The study suggests substantial harms associated with cancer care disruptions during the COVID-19 pandemic.
Tumor-associated neutrophils assume multiple functional states, but one gene expression program supports cancer cell survival and tumor progression across tumor types. A biomarker called CCL3 functionally supports cancer growth by engaging a receptor on the surface of TANs to transmit signals that drive them toward an aged state.
Researchers developed BrainIAC, a robust AI foundation model that analyzes brain MRI datasets to identify key neurological health indicators. The tool outperformed conventional AI models in diverse tasks, including predicting dementia risk and detecting brain tumor mutations.
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The 4-1BB-containing CAR design emerged as superior, demonstrating strongest anti-tumor activity and persistence.
The National Comprehensive Cancer Network (NCCN) has committed to updating its robust information resources for cancer patients and caregivers annually, available in both English and Spanish. The updated resources will provide factual, trustworthy information to guide patients and caregivers towards their best possible outcome.
A new study reveals that the surrounding microenvironment plays a crucial role in driving basal cell development, leading to treatment failure. The study also discovers intermediate tumor subtypes that could lead to new therapeutic strategies.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
A Mass General Brigham-led study found that integrating feedback and personalized palliative care can improve the quality of life for children with advanced cancer. The study showed significant improvements in symptoms and well-being for patients who received the intervention, highlighting the potential benefits of early palliative care.
Researchers at Salk Institute uncover two transcription factors, ZSCAN20 and JDP2, that determine T cell fate. Turning off these genes reverses T cell exhaustion and restores their ability to kill tumors without losing immune memory. The study challenges the long-standing belief of inevitable immune exhaustion.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
George Coukos directs the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine's Sandra and Edward Meyer Cancer Center. The lab focuses on developing personalized cellular immunotherapies to optimize cancer treatment strategies.